The safety and efficacy of systemic delivery of a new liver-de-targeted TGFβ signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary tumor model.
Saved in:
| Title: | The safety and efficacy of systemic delivery of a new liver-de-targeted TGFβ signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary tumor model. |
|---|---|
| Authors: | Shin SC; Cancer Gene Therapy Program, Department of Medicine, NorthShore University HealthSystem, an Academic Affiliate of the University of Chicago Pritzker School of Medicine, Endeavor Health Medical Group, Evanston, IL, USA., Vickman RE; Center for Personalized Cancer Care, Department of Surgery, NorthShore University HealthSystem, an Academic Affiliate of the University of Chicago Pritzker School of Medicine, Endeavor Health Medical Group, Evanston, IL, USA., Filimon B; Cancer Gene Therapy Program, Department of Medicine, NorthShore University HealthSystem, an Academic Affiliate of the University of Chicago Pritzker School of Medicine, Endeavor Health Medical Group, Evanston, IL, USA., Yang Y; Cancer Gene Therapy Program, Department of Medicine, NorthShore University HealthSystem, an Academic Affiliate of the University of Chicago Pritzker School of Medicine, Endeavor Health Medical Group, Evanston, IL, USA.; Department of Experimental Medical Science and Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo, China., Hu Z; Cancer Gene Therapy Program, Department of Medicine, NorthShore University HealthSystem, an Academic Affiliate of the University of Chicago Pritzker School of Medicine, Endeavor Health Medical Group, Evanston, IL, USA.; National Institutes for Food and Drug Control, Beijing, China., Mangold KA; Department of Pathology and Laboratory Medicine, NorthShore University HealthSystem, Endeavor Health Medical Group, Evanston, IL, USA.; Department of Pathology, The University of Chicago, Chicago, IL, USA., Prabhakar BS; Department of Microbiology and Immunology, University of Illinois College of Medicine, Chicago, IL, USA., Schreiber H; Department of Pathology, The University of Chicago, Chicago, IL, USA., Xu W; Cancer Gene Therapy Program, Department of Medicine, NorthShore University HealthSystem, an Academic Affiliate of the University of Chicago Pritzker School of Medicine, Endeavor Health Medical Group, Evanston, IL, USA. WXu@northshore.org. |
| Source: | Cancer gene therapy [Cancer Gene Ther] 2024 Apr; Vol. 31 (4), pp. 574-585. Date of Electronic Publication: 2024 Jan 24. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9432230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5500 (Electronic) Linking ISSN: 09291903 NLM ISO Abbreviation: Cancer Gene Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38267626 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: The safety and efficacy of systemic delivery of a new liver-de-targeted TGFβ signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary tumor model. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Shin+SC%22">Shin SC</searchLink>; Cancer Gene Therapy Program, Department of Medicine, NorthShore University HealthSystem, an Academic Affiliate of the University of Chicago Pritzker School of Medicine, Endeavor Health Medical Group, Evanston, IL, USA.<br /><searchLink fieldCode="AU" term="%22Vickman+RE%22">Vickman RE</searchLink>; Center for Personalized Cancer Care, Department of Surgery, NorthShore University HealthSystem, an Academic Affiliate of the University of Chicago Pritzker School of Medicine, Endeavor Health Medical Group, Evanston, IL, USA.<br /><searchLink fieldCode="AU" term="%22Filimon+B%22">Filimon B</searchLink>; Cancer Gene Therapy Program, Department of Medicine, NorthShore University HealthSystem, an Academic Affiliate of the University of Chicago Pritzker School of Medicine, Endeavor Health Medical Group, Evanston, IL, USA.<br /><searchLink fieldCode="AU" term="%22Yang+Y%22">Yang Y</searchLink>; Cancer Gene Therapy Program, Department of Medicine, NorthShore University HealthSystem, an Academic Affiliate of the University of Chicago Pritzker School of Medicine, Endeavor Health Medical Group, Evanston, IL, USA.; Department of Experimental Medical Science and Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo, China.<br /><searchLink fieldCode="AU" term="%22Hu+Z%22">Hu Z</searchLink>; Cancer Gene Therapy Program, Department of Medicine, NorthShore University HealthSystem, an Academic Affiliate of the University of Chicago Pritzker School of Medicine, Endeavor Health Medical Group, Evanston, IL, USA.; National Institutes for Food and Drug Control, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Mangold+KA%22">Mangold KA</searchLink>; Department of Pathology and Laboratory Medicine, NorthShore University HealthSystem, Endeavor Health Medical Group, Evanston, IL, USA.; Department of Pathology, The University of Chicago, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Prabhakar+BS%22">Prabhakar BS</searchLink>; Department of Microbiology and Immunology, University of Illinois College of Medicine, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Schreiber+H%22">Schreiber H</searchLink>; Department of Pathology, The University of Chicago, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Xu+W%22">Xu W</searchLink>; Cancer Gene Therapy Program, Department of Medicine, NorthShore University HealthSystem, an Academic Affiliate of the University of Chicago Pritzker School of Medicine, Endeavor Health Medical Group, Evanston, IL, USA. WXu@northshore.org. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229432230%22">Cancer gene therapy</searchLink> [Cancer Gene Ther] 2024 Apr; Vol. 31 (4), pp. 574-585. <i>Date of Electronic Publication: </i>2024 Jan 24. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9432230 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1476-5500 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209291903%22">09291903 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Gene Ther <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38267626 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41417-024-00735-1 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 574 Titles: – TitleFull: The safety and efficacy of systemic delivery of a new liver-de-targeted TGFβ signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary tumor model. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Shin SC – PersonEntity: Name: NameFull: Vickman RE – PersonEntity: Name: NameFull: Filimon B – PersonEntity: Name: NameFull: Yang Y – PersonEntity: Name: NameFull: Hu Z – PersonEntity: Name: NameFull: Mangold KA – PersonEntity: Name: NameFull: Prabhakar BS – PersonEntity: Name: NameFull: Schreiber H – PersonEntity: Name: NameFull: Xu W IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: 2024 Apr Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 1476-5500 Numbering: – Type: volume Value: 31 – Type: issue Value: 4 Titles: – TitleFull: Cancer gene therapy Type: main |
| ResultId | 1 |
